Semnur Pharmaceuticals, Inc. (SMNR)

Market Cap	1.15B +874.9%
Revenue (ttm)	n/a
Net Income	-160.42M
EPS	-0.78
Shares Out	230.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148
Average Volume	259
Open	5.00
Previous Close	n/a
Day's Range	5.00 - 5.00
52-Week Range	4.50 - 23.00
Beta	0.18
RSI	33.88
Earnings Date	May 5, 2026

About Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: SMNR